NCT02161952View on ClinicalTrials.gov

Pirfenidone, an Antifibrotic and Antiinflammatory Drug

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2007

Conditions
FibrosisHepatitis C Chronic
Interventions
DRUG

Pirfenidone

Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.

DRUG

Matched equivalent placebo

All Listed Sponsors
collaborator

Cell Therapy And Technology, S.a. De C.v.

INDUSTRY

lead

University of Guadalajara

OTHER

NCT02161952 - Pirfenidone, an Antifibrotic and Antiinflammatory Drug | Biotech Hunter | Biotech Hunter